Conflicts cause FDA to review advisory committees

CMAJ. Canadian Medical Association Journal

Volumn 175, Issue 1, 2006, Pages 23-24

  Kondro, Wayne ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ROFECOXIB; VALDECOXIB;

ADVISORY COMMITTEE; BUDGET; CONFLICT OF INTEREST; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; HUMAN; REVIEW; ARTICLE; ETHICS; MEDICAL ETHICS; ORGANIZATION AND MANAGEMENT; UNITED STATES;

ADVISORY COMMITTEES; CONFLICT OF INTEREST; DRUG INDUSTRY; ELIGIBILITY DETERMINATION; ETHICS, PROFESSIONAL; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33745921216     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.060636     Document Type: Review

References (5)

1. Lurie P, Almeida CM, Stine N, et al; Public Citizen's Health Research Group. Financial conflict of interest disclosure and voting patterns at Food and Drug Administration Drug Advisory Committee meetings. JAMA 2006;295;1921-8.
2. Harris G, Berenson A. Ten voters on panel backing pain pills had industry ties: the 10 government drug advisers with company ties voted 9 to 1 to keep Bextra on the market and 9 to 1 for Vioxx's return. New York Times 2005 Feb 25. An article of the same topic, date and authorship is available: www.sfgate.com/cgi-bin/article.cgi?f=/c/a/2005/02 /25/MNGJTBGQ7H1.DTL (accessed 2007 June 7).
3. Eggertson L. Breast implant advisory panel: more study on silicone leakage [news item]. CMAJ 2006; 174(4):443-4.
4. Center for Science in the Public Interest. FDA panel investigating labeling of antihypertensive drugs stacked with industry consultants: draft guidance may miss opportunity to educate Americans about importance of lifestyle, diet on high blood pressure [press release]. Washington: The Center; 2006 Apr 24. Available through www.cspinet.org/integrity /press_releases.html (accessed 2007 June 7).
5. Henderson D. No end to FDA disclosure debate: new waiver law fails to quiet criticism over experts' financial ties to drug companies. Boston Globe 2006 Apr 21. Available: www.boston.com/business/articles/2006/04/21/ no_end_to_fda_disclosure_debate (accessed 2006 June 7).